Home/ Stocks/ PVLA

Palvella Therapeutics, Inc. Common Stock

PVLA XNAS

$116.23 +0.00 (+0.00%) ▲ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$1.67B

About Palvella Therapeutics, Inc. Common Stock

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 14 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$628.0K	$-11,345,000	$-1.03
Q2 2025	$690.0K	$-9,471,000	$-0.86
Q1 2025	$752.0K	$-8,185,000	$-0.74
FY 2024	$0	$-17,434,000	$-7.83

Earnings & Analyst Ratings

Next Earnings: Wed, May 13, 2026

Calendar →

TickerDaily Coverage

Why Is Palvella Therapeutics, Inc. Common Stock (PVLA) Stock Up 36.6% Today?

Market News Alex Chen · Feb 24, 2026

Palvella Therapeutics (PVLA) stock ripped 36.6% higher today following a conference call...

View All Coverage →

Get PVLA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Palvella Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.